ACAD vs ISRG
ACADIA Pharmaceuticals Inc. vs Intuitive Surgical — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
66
Buy
VS
ISRG
Intuitive Surgical
60
Buy
| Metric | ACAD | ISRG |
|---|
| AI Score |
66
|
60
|
| Price |
$30.59
|
$371.73
|
| P/E Ratio |
13.18×
|
42.21×
|
| ROE |
31.9%
|
16.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
66.7%
|
| Debt / Equity |
0.06×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
61.2
|
40.0
|
| Beta |
0.845
|
1.46
|
| Expected Upside |
—
|
+18.5%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus ISRG.
ACAD leads by 6 points.
ACAD scores 66/100 (Buy) versus ISRG at 60/100 (Buy).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 21.2% signals elevated volatility — Risk
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical